MiRNAs Evaluate the Prognosis of Sepsis by Dynamic Study

MiRNAhs in the Evaluation of the Value of Sepsis Prognosis Dynamics Observational Research

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01459822

Acronym

METPSDS

Enrollment

Registered

2011-10-26

Start date

2011-08-31

Completion date

2013-09-30

Last updated

2011-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Keywords

sepsis, miRNA

Brief summary

Sepsis is a common cause of death in intensive care unit, timely and accurate diagnosis and treatment directly affect the survival rate. MiRNA is a post-transcriptional small RNA which regulate mRNA expression. The present study was designed to observe the selected miRNA expression which evaluate the sepsis prognosis in the progression of sepsis in order to be a new target for the treatment of sepsis.

Detailed description

The study is a non-intervention observational study. Purpose of this study is to observe some selected miRNA expression which evaluate the sepsis prognosis in the progression of sepsis . The investigators will collect serum samples from patients with sepsis in SICU, RICU and EICU on the 1st、3rd、5th、7th、10th、14th day of 301 Hospital since November 2011 , and then use mirVana PARIS kit extract total RNA and use qRT-PCR detect miRNAS expression in serum which can evaluate the prognosis of sepsis, and statistical analysis the miRNAS expression correlation with SOFA score.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Clinical diagnosis of sepsis * Patients who agree with the study

Exclusion criteria

* Aged \<18 years; * Into the group who died within 24 hours; * Agranulocytosis (\<0.5 × 109 / L); * Combined HIV infection.

Design outcomes

Primary

Measure	Time frame
all cause mortality	28days after admited in ICU

Countries

China

Contacts

Primary ContactJie Deng, master

172534784@qq.com+86 18610095120

Outcome results